Related references
Note: Only part of the references are listed.Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications
Giada Bianchi et al.
BLOOD (2010)
Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future
Adam J. Waxman et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study
Martin Hjorth et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis
Arun Balakumaran et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2010)
Multiple Myeloma Precursor Disease
Ola Landgren et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
Jens Hillengass et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
Angela Dispenzieri et al.
LANCET (2010)
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management
R. A. Kyle et al.
LEUKEMIA (2010)
Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma
Sham Mailankody et al.
LEUKEMIA & LYMPHOMA (2010)
Advances in the Diagnosis, Classification, Risk Stratification, and Management of Monoclonal Gammopathy of Undetermined Significance: Implications for Recategorizing Disease Entities in the Presence of Evolving Scientific Evidence
S. Vincent Rajkumar et al.
MAYO CLINIC PROCEEDINGS (2010)
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study
Ola Landgren et al.
BLOOD (2009)
A monoclonal gammopathy precedes multiple myeloma in most patients
Brendan M. Weiss et al.
BLOOD (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance
Celine M. Vachon et al.
BLOOD (2009)
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation
Jens Hillengass et al.
CLINICAL CANCER RESEARCH (2009)
The Potential Role of Curcumin in Patients with Monoclonal Gammopathy of Undefined Significance-Its Effect on Paraproteinemia and the Urinary N-Telopeptide of Type I Collagen Bone Turnover Marker
Terry Golombick et al.
CLINICAL CANCER RESEARCH (2009)
Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context
Laura Chiecchio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case
Laura Chiecchio et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies
Sigurdur Y. Kristinsson et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
R. Fonseca et al.
LEUKEMIA (2009)
International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma
M. Dimopoulos et al.
LEUKEMIA (2009)
Induction of a Chronic Disease State in Patients With Smoldering or Indolent Multiple Myeloma by Targeting Interleukin 1β-Induced Interleukin 6 Production and the Myeloma Proliferative Component
John A. Lust et al.
MAYO CLINIC PROCEEDINGS (2009)
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Bart Barlogie et al.
BLOOD (2008)
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
Angela Dispenzieri et al.
BLOOD (2008)
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
Pellegrino Musto et al.
CANCER (2008)
AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies
Marta Chesi et al.
CANCER CELL (2008)
Clinical and biological significance of RAS mutations in multiple myeloma
W. J. Chng et al.
LEUKEMIA (2008)
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Flavia Pichiorri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Clinically relevant end points and new drug approvals for myeloma
K. C. Anderson et al.
LEUKEMIA (2008)
Prevalence of monoclonal Gammopathy of undetermined significance among men in Ghana
Ola Landgren et al.
MAYO CLINIC PROCEEDINGS (2007)
Genetic events in the pathogenesis of multiple myeloma
W. J. Chng et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells
Ernesto Perez-Persona et al.
BLOOD (2007)
Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma
Christina M. Annunziata et al.
CANCER CELL (2007)
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma
Robert A. Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis
Fenghuang Zhan et al.
BLOOD (2007)
microRNAs as oncogenes and tumor suppressors
Baohong Zhang et al.
DEVELOPMENTAL BIOLOGY (2007)
Prevalence of monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States
O Landgren et al.
BLOOD (2006)
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
L. Chiecchio et al.
LEUKEMIA (2006)
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
SV Rajkumar et al.
BLOOD (2005)
Fracture risk with multiple myeloma: A population-based study
LJ Melton et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors
T Rasmussen et al.
BLOOD (2005)
Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity
K Asosingh et al.
BLOOD (2004)
Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes
B Sáez et al.
LEUKEMIA (2004)
Drug therapy: Multiple myeloma
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
R Fonseca et al.
BLOOD (2003)
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma
CS Debes-Marun et al.
LEUKEMIA (2003)
Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases
NV Smadja et al.
GENES CHROMOSOMES & CANCER (2003)
A long-term study of prognosis in monoclonal gammopathy of undetermined significance
RA Kyle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Thalidomide for previously untreated indolent or smoldering multiple myeloma
SV Rajkumar et al.
LEUKEMIA (2001)
Share Paper
